%0 Journal Article %T Prospect and Current Situation of Immune Checkpoint Inhibitors £¿in First-line Treatment in Advanced Non-small Cell Lung Cancer Patients %A Haiyang WANG %A Xiaoqing YU %A Yun FAN %J Öйú·Î°©ÔÓÖ¾ %D 2017 %R : 10.3779/j.issn.1009-3419.2017.06.10 %X With the breakthroughs achieved of programmed death-1 (PD-1)/PD-L1 inhibitors monotherapy as first-line and second-line treatment in advanced non-small cell lung cancer (NSCLC), the treatment strategy is gradually evolving and optimizing. Immune combination therapy expands the benefit population and improves the curative effect. A series of randomized phase III trials are ongoing. In this review, we discuss the prospect and current situation of immune checkpoint inhibitors in first-line treatment in advanced NSCLC patients. %K PD-1/PD-L1 inhibitors %K Lung neoplasms %K First-line treatment %U http://www.lungca.org/index.php?journal=01&page=article&op=view&path%5B%5D=10.3779%2Fj.issn.1009-3419.2017.06.10